JPRN-UMIN000021619
Completed
未知
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on biomarkers in early diabetic nephropathy in Japanese with type 2 diabetes - Nephropathy markers in type 2 diabetes with sodium-glucose co-transporter 2 (SGLT2) inhibitors
Yokohama City University Graduate School of Medicine0 sites20 target enrollmentMarch 31, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yokohama City University Graduate School of Medicine
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients corresponding to any of the following are inapplicable 1\) Patients with a history of allergy to any component of the study medications 2\)Patients with severe complications( liver disease, mental disorder, cancer) 3\)Patients with severe ketosis or diabetic coma. 4\)Patients with severe infections, perioperative status, or severe trauma 5\) Patients whose baseline eGFR were \<29 ml/min/1\.73m^2 6\) Patients with kidney disease other than diabetic nephropathy.(Specifically, patients with occult blood positive) Patients with renal transplantations, or using drugs with nephrotoxic. 7\)Pregnancy or lactation in women 8\)Inadequacy of usingig this therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on metabolic parameters in patients with type 2 diabetes: A chart-based analysistype 2 diabetesJPRN-UMIN000020314ational Center for Global Health and Medicine Kohnodai Hospital75
Completed
Phase 4
Effect of SGLT2 inhibitors on heart function in type 2 diabetic patients in south IndiaHealth Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2020/02/023195izams Institute of Medical Sciences
Recruiting
Not Applicable
Effects of sodium-glucose co-transporter2(SGLT2) inhibitors on left ventricular systolic and/or diastolic dysfunction in Japanese type2 diabetesType2 diabetic patients with systolic and/or diastolic dysfunctionJPRN-UMIN000025841Kanagawa Cardiovascular and Respiratory Center30
Terminated
Not Applicable
Effects of Sodium Glucose Co-Transpoter-2 (SGLT-2) in diabetics with heart failureHeart failureType 2 DiabetesCardiovascular - Other cardiovascular diseasesMetabolic and Endocrine - DiabetesACTRN12618000795291Endcrinology Department, Box Hill Hospital - Eastern Health2
Not yet recruiting
Phase 4
Effects of SGLT2 Inhibitor Therapy on Pancreatic and hepatic fat content in patients of Type 2 Diabetes MellitusCTRI/2019/08/020909ASTRA ZENECA PHARMACEUTICAL INDIA